Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis

Thrombosis and Haemostasis

Volumn 75, Issue 6, 1996, Pages 902-907

  Mesters, R M ^a   Florke N ^a   Ostermann, H ^a   Kienast, J ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTIINFECTIVE AGENT; FIBRIN DEGRADATION PRODUCT; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEVER; FIBRINOLYSIS; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; SEPTIC SHOCK;

EID: 0029855166     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650392     Document Type: Article

References (42)

1. American college of chest physicians/society of critical care medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74.
2. Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: pathogenesis Lancet 1991; 338: 732-6.
3. Bone RC. Modulators of coagulation. A critical appraisal of their role in sepsis. Arch Intern Med 1992; 152: 1381-9.
4. Levi M, ten Gate H, van der Poll T, van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-9.
5. Carrico CJ, Meakins JL, Marshall JC, Fry D. Maier RV. Multiple organ failure syndrome. Arch Surg 1986; 121: 196-208.
6. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A. Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Chest 1992; 101: 816-23.
7. Thijs LG, de Boer JP, de Groot MCM, Hack CE. Coagulation disorders in septic shock. Intensive Care Med 1993; 19: 8-15.
8. Voss R, Matthias FR, Borkowski G, Reitz D. Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br J Haematol 1990; 75: 99-102.
9. Hesselvik JF, Blombäck M, Brodin B, Maller R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med 1989; 17: 724-33.
10. Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E, Garcia-Avello A. Time course of hemostatic abnormalities in sepsis and its relation to out-come. Chest 1993; 103: 1536-42.
11. Philippe J, Offner F, Declerck PJ, Leroux-Roels G, Vogelaers D, Baele G, Collen D. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost 1991; 65: 291-5.
12. Pralong G, Calandra T, Glauser M-P, Schellekens J, Verhoef J, Bachmann F, Kruithof EKO. Plasminogen activator inhibitor I: a new prognostic marker in septic shock. Thromb Haemost 1989; 61: 459-62.
13. Brandtzaeg P, Joo GB, Brusletto B, Kiemlf P. Plasminogen activator inhibitor I and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990; 57: 271-8.
14. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323-32.
15. Declerck PJ, Alessi M-C, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-5.
16. Stief TW, Lenz P, Becker U, Heimburger N. Determination of plasminogen activator inhibitor (PAI) capacity of human plasma in the presence of oxidants: a novel principle. Thromb Res 1988; 50: 559-73.
17. Marder VJ, Feinstein DI, Francis CW, Colman RW. Consumptive thrombohemorrhagic disorders. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW (eds). J.B. Lippincott Company, Philadelphia, PA 1994; pp 1023-63.
18. Van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-6.
19. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-72.
20. van der Poll T, Levi M, Büller HR, van Deventer SJH, de Boer JP, Hack CE, ten Cate JW. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174: 729-32.
21. van Hinsbergh VWM, Bauer KA, Kooistra T, Kluft C, Dooijewaard G, Sherman ML, Nieuwenhuizen W. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 1990; 76: 2284-9.
22. Silverman P, Goldsmith GH, Spitzer TR, Rehmus EH, Berger NA. Effect of tumor necrosis factor on the human fibrinolytic system. J Clin Oncol 1990; 8: 468-75.
23. De Boer JP, Creasy AA, Chang A, Roem D, Brouwer MC, Eerenberg AJM, Hack CE, Taylor FB Jr. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of escherichia coli. Circ Shock 1993; 39: 59-67.
24. Levi M, ten Cale H, Bauer KA, van der Poll T, Edgington TS, Büller HS, van Deventer SJH, Hack CE, ten Gate IW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-20.
25. 23,). Blood 1995; 85: 3437-43.
26. Siebeck M, Spannagl M, Hoffmann H, Schramm W, Fritz H. Time dependent release of tissue-type plasminogen activator and plasminogen activator inhibitor into the circulation of pigs during septic shock. Blood Coagul Fibrinolysis 1991; 2: 459-64.
27. Haj MA, Neilly IJ, Robbie LA, Adey CD. Bennett B. Influence of white blood cells on the fibrinolytic response to sepsis: studies of septic patients with or without severe leucopenia. Br J Haematol 1995; 90: 541-7.
28. Saito M, Asakura H, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Yoshida T, Aoshima K, Matsuda T. Haemostatic and fibrinolytic parameters in septic patients with leukopenia or leukocytosis. Eur J Haematol 1995; 54: 176-9.
29. Paramo JA, Perez JL, Serrano M, Rocha E. Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. Throrab Haeinost 1990; 64: 3-6.
30. Haj MA, Robbie LA, Adey GD, Bennett B. Inhibitors of plasminogen activator in neutrophils and mononuclear cells from septic patients. Thromb Haemost 1995; 74: 1528-32.
31. Booth NA, Simpson AJ, Croll A, Bennetl B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-33.
32. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1989; 260: 11581-7.
33. De Boer JP, Abbink JJ, Brouwer MC, Meijer C, Roem D, Voorn GP, Lambers JWJ, van Mourik JA, Hack CE, PAI-1 synthesis in the human hepatoma cell line Hep G2 is increased by cytokines. Evidence that the liver contributes to acute phase behaviour of PAI-1. Thromb Haemost 1991; 65: 181-5.
34. Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991; 44: 139-43.
35. Colucci M, Paramo JA, Collen D. Generation in plasma of a fast acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818.
36. Emeis JJ, Kooistra T. Interleukin I and lipopoiysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-6.
37. Nachman RL, Hajjar KA, Silverstein RL, Dinarello CA. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1986; 163: 1595-1600.
38. Bevilacqua MP, Schleef RR, Gimbrone MA Jr, Loskutoff DJ. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin I. J Clin Invest 1985; 78: 587-91.
39. van Hinsbergh VWM, Kooistra T, van den Berg EA, Princen HMG, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and rats in vivo. Blood 1988; 72: 1467-73.
40. Gelehrter TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1986; 165-9.
41. Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 1989; 74: 222-8.
42. Paloma MJ, Paramo JA, Rocha E. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase on PAI generation, fibrin deposits and mortality. Throrab Haemost 1995; 74: 1578-82.